Federal Register / Vol. 61, No. 85 / Wednesday, May 1, 1996 / Notices 19305

1The NTP uses five categories of evidence of

carcinogenic activity observed in each animal

study: two categories for positive results (‘‘clear

evidence’’ and ‘‘some evidence’’), one category for

uncertain findings (‘‘equivocal evidence’’), one

category for no observable effect (‘‘no evidence’’)

and one category for studies that cannot be

evaluated because of major flaws (‘‘inadequate

study’’).

1. Applications shall be considered as

meeting the deadline if they are either:

a. Received on or before the stated

deadline date; or

b. Sent on or before the deadline date

and received in time for submission to

the objective review group. (Applicants

must request a legibly dated U.S. Postal

Service postmark or obtain a legibly

dated receipt from a commercial carrier

or the U.S. Postal Service. Private

metered postmarks shall not be accepted

as proof of timely mailing.)

2. Late Applications:

Applications which do not meet the

criteria in 1.a. or 1.b., above, are

considered late applications. Late

applications will not be considered in

the current competition and will be

returned to the applicant.

Where To Obtain Additional

Information

A complete program description,

information on application procedures,

an application package, and business

management technical assistance may

be obtained from Nealean K. Austin,

Grants Management Specialist, Grants

Management Branch, Procurement and

Grants Office, Centers for Disease

Control and Prevention (CDC), 255 East

Paces Ferry Road, NE., Room 314,

Mailstop E–18, Atlanta, GA 30305,

telephone (404) 842–6508; by fax (404)

842–6513; by Internet or CDC WONDER

electronic mail at

nea1@opspgo1.em.cdc.gov.

Programmatic technical assistance

may be obtained from Kevin Brady,

MPH, Acting Assistant Branch Chief for

Management and Operations, Program

Services Branch, Division of Cancer

Prevention and Control, National Center

for Chronic Disease Prevention and

Health Promotion, Centers for Disease

Control and Prevention (CDC), 4770

Buford Highway, NE., Mailstop K–57,

Atlanta, GA 30341–3724, telephone

(404) 488–4880 and by fax (404) 488–

4727; by Internet or CDC WONDER

electronic mail at

KBB2@ccdpcp1.em.cdc.gov.

Please refer to Program

Announcement Number 623 when

requesting information and submitting

an application.

Potential applicants may obtain a

copy of ‘‘Healthy People 2000’’ (Full

Report, Stock No. 017–001–00474–0) or

‘‘Healthy People 2000’’ (Summary

Report, Stock No. 017–001–00473–1)

referenced in the Introduction through

the Superintendent of Documents,

Government Printing Office,

Washington, DC 20402– 9325, telephone

(202) 512–1800.

There may be delays in mail delivery

and difficulty in reaching the CDC

Atlanta offices during the 1996 Summer

Olympics. Therefore, CDC suggests

using Internet, following all instructions

in this announcement and leaving

messages on the contact person’s voice

mail for more timely responses to any

questions.

Dated: April 24, 1996.

Joseph R. Carter,

Acting Associate Director for Management

and Operations, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 96–10778 Filed 4–30–96; 8:45 am]

BILLING CODE 4163–18–P

Public Health Service

National Toxicology Program;

Availability of Technical Report on

Toxicology and Carcinogenesis

Studies of t-Butyl Alcohol

The HHS’ National Toxicology

Program announces the availability of

the NTP Technical Report on the

toxicology and carcinogenesis studies of

t-butyl alcohol. t-Butyl alcohol is widely

used in the manufacture of perfumes

and a variety of cosmetics.

Toxicology and carcinogenicity

studies were conducted by

administration of t-butyl alcohol, in

drinking water to groups of 60 F344/N

rats of each sex at doses of 0, 1.25, 2.5,

or 5 mg/mL for males and 0, 2.5, 5, or

10 mg/mL for females. Groups of 60

B6C3F1 mice of each sex received t-butyl

alcohol in drinking water at does of 0,

5, 10, or 20 mg/mL.

Under the conditions of these 2-year

drinking water studies, there was some

evidence of carcinogenic activity 1 of tbutyl alcohol in male F344/N rats based

on increased incidences of renal tubule

adenoma or carcinoma (combined).

There was no evidence of carcinogenic

activity of t-butyl alcohol in female

F344/N rats receiving 2.5, 5 or 10 mg/

mL. There was equivocal evidence of

carcinogenic activity in male B6C3F1

mice based on marginally increased

incidences of follicular cell adenoma or

carcinoma (combined) of the thyroid

gland. There was some evidence of

carcinogenic activity of t-butyl alcohol

in female B6C3F1 mice based on

increased incidences of follicular cell

adenoma of the thyroid gland.

Questions or comments about the

Technical Report should be directed to

Central Data Management at P.O. Box

12233, Research Triangle Park, NC

27709 or telephone (919) 541–3419.

Copies of Toxicology and

Carcinogenesis Studies of t-Butyl

Alcohol (CAS No. 75–65–0) (TR–436)

are available without charge from

Central Data Management, NIEHS, MD

E1–02, P.O. Box 12233, Research

Triangle Park, NC 27709; telephone

(919) 541–3419.

Dated: April 27, 1996.

Kenneth Olden,

Director, National Toxicology Program.

[FR Doc. 96–10832 Filed 4–30–96; 8:45 am]

BILLING CODE 4140–01–M

National Toxicology Program;

Availability of Technical Report on

Toxicology and Carcinogenesis

Studies of Diethylphthalate with

Dermal Initiation/Promotion Study of

Diethylphthalate and

Dimethylphthalate

The HHS’ National Toxicology

Program announces the availability of

the NTP Technical Report on the

toxicology and carcinogenesis studies of

Diethylphthalate. Diethylphthalate and

Dimethylphthalate are used as phthalte

plasticizers in an extensive array of

products.

Toxicology and carcinogenicity

studies were conducted by dermal

administration of diethylphthalate to

groups of 60 F344/N rats of each sex at

doses of 0, 100, or 300 μL and to groups

of 60 B6C3F1 mice of each sex at doses

of 0, 7.5, 15, or 30 μL. Neat chemical

was applied to rats for 5 days per week

for 103 weeks and up to 10 animals per

group were evaluated after 15 months.

Mice received doses in 100 μL of

acetone for 5 days per week for 103

weeks with a 1 week recovery period,

and up to 10 animals per group were

evaluated after 15 months.

An additional group of 50 male Swiss

(CD–1) mice were dosed dermally with

diethylphthalate of dimethylphthalate

to study their effect as initiators and

promoters. They were tested as

initiators with and without 12–

Otetradecanoylphorbol and they were

tested as promoters with and without

the known skin tumor initiator 7,12-

dimethylbenzanthrancene.

Under the conditions of these 2-year

dermal studies, there was no evidence

of carcinogenic activity 1 of
19306 Federal Register / Vol. 61, No. 85 / Wednesday, May 1, 1996 / Notices

1The NTP uses five categories of evidence of

carcinogenic activity observed in each animal

study: two categories for positive results (‘‘clear

evidence’’ and ‘‘some evidence’’), one category for

uncertain findings (‘‘equivocal evidence’’), one

category for no observable effect (‘‘no evidence’’),

and one category for studies that cannot be

evaluated because of major flaws (‘‘inadequate

study’’).

1The NTP uses five categories of evidence of

carcinogenic activity observed in each animal

study: two categories for positive results (‘‘clear

evidence’’ and ‘‘some evidence’’), one category for

uncertain findings (‘‘equivocal evidence’’), one

category for no observable effect (‘‘no evidence’’),

and one category for studies that cannot be

evaluated because of major flaws (‘‘inadequate

study’’).

1The NTP uses five categories of evidence of

carcinogenic activity observed in each animal

study: two categories for positive results (‘‘clear

evidence’’ and ‘‘some evidence’’), one category for

uncertain findings (‘‘equivocal evidence’’), one

category for no observable effect (‘‘no evidence’’),

and one category for studies that cannot be

evaluated because of major flaws (‘‘inadequate

study’’).

diethylphthalate in male or female

F344/N rats receiving 100 or 300 μL.

There was equivocal evidence of

carcinogenic activity of diethylphthalate

in male and female B6C3F1 mice based

on increased incidences of

hepatocellular neoplasms, primarily

adenomas.

In the initiation/promotion model,

there was no evidence of initiating or

promoting activity of diethylphthalate

or dimethylphthalate in male Swiss

(CD–1) mice.

Questions or comments about the

Technical Report should be directed to

Central Data Management at P.O. Box

12233, Research Triangle Park, NC

27709 or telephone (919) 541–3419. Copies of Toxicology and

Carcinogenesis Studies of

Diethylphthalate/Dimethylphthalate

(CAS Nos. 84–66–2 and 131–11–3) (TR–

429) are available without charge from

Central Data Management, NIEHS, MD

E1–02, P.O. Box 12233, Research

Triangle Park, NC 27709; telephone

(919) 541–3419.

Dated: March 27, 1996

Kenneth Olden,

Director, National Toxicology Program.

[FR Doc. 96–10833 Filed 4–30–96; 8:45 am]

BILLING CODE 4140–01–M

National Toxicology Program;

Availability of Technical Report on

Toxicology and Carcinogenesis

Studies of Benzethonium Chloride

The HHS’ National Toxicology

Program announces the availability of

the NTP Technical Report on the

toxicology and carcinogenesis studies of

benzethonium chloride, which is used

primarily in cosmetics for its

antimicrobial and cationic surfactant

properties.

Toxicology and carcinogenicity

studies were conducted by dermal

administration of benzethonium

chloride to groups of 60 F344/N rats and

60 B6C3F1 mice of each sex at doses of

0, 0.15, 0.5, or 1.5 mg/kg body weight.

Benzethonium chloride was

administered to rats in ethanol 5 days

per week and doses were adjusted

weekly according to the average body

weights of the groups. As many as nine

rats per group were evaluated after 15

months. Mice received doses

administered in ethanol and dose

volumes were adjusted weekly

according to average body weights of the

groups. As many as ten mice per group

were evaluated after 15 months of

chemical administration.

Under the conditions of these 2-year

dermal studies, there was no evidence

of carcinogenic activity 1 of

benzethonium chloride in male or

female F344 rats or in male or female

B6C3F1 mice.

Exposure of rats and mice to

benzethonium chloride by dermal

application in ethanol for 2 years

resulted in epithelial hyperplasia in

male and female rats and mice and

sebaceous gland hyperplasia and ulcers

in female rats at the site of application.

Questions or comments about the

Technical Report should be directed to

Central Data Management at P.O. Box

12233, Research Triangle Park, NC

27709 or telephone (919) 541–3419.

Copies of Toxicology and

Carcinogenesis Studies of

Benzethonium Chloride (CAS No. 121–

54–0) (TR–438) are available without

charge from Central Data Management,

NIEHS, MD E1–02, P.O. Box 12233,

Research Triangle Park, NC 27709;

telephone (919) 541–3419.

Dated: April 12, 1996.

Kenneth Olden,

Director, National Toxicology Program.

[FR Doc. 96–10834 Filed 4–30–96; 8:45 am]

BILLING CODE 4140–01–M

National Toxicology Program;

Availability of Technical Report on

Toxicology and Carcinogenesis

Studies of o-Benzyl-p-Chlorophenol

The HHS’ National Toxicology

Program announces the availability of

the NTP Technical Report on the

toxicology and carcinogenesis studies of

o-benzyl-p-chlorophenol. o-Benzyl-pchlorophenol, an aryl halide, is a broad

spectrum germicide used in disinfectant

solutions and soap formulations in

United States hospitals and households.

Human exposure to o-benzyl-pchlorophenol occurs by absorption

through the skin and mucous

membranes and by ingestion.

Toxicology and carcinogenicity

studies were conducted by dermal

administration of o-benzyl-pchlorophenol to groups of 50 Swiss

(CD–1) mice of each sex to study its

effect as an initiator, promoter, and

complete carcinogen.

Under the conditions of the 1-year

mouse skin initiation/promotion study

in Swiss (CD–1) mice, o-benzyl-pchlorophenol was a cutaneous irritant

and a weak skin tumor promoter relative

to strong promoters such as 12-Otetradecanoylphorbol-13-acetate. oBenzyl-p-chlorophenol had no activity

as an initiator or as a complete

carcinogen.1

Questions or comments about the

Technical Report should be directed to

Central Data Management at P.O. Box

12233, Research Triangle Park, NC

27709 or telephone (919) 541–3419.

Copies of Toxicology and

Carcinogenesis Studies of o-Benzyl-pChlorophenol (CAS No. 120–32–1) TR–

444) are available without charge from

Central Data Management, NIEHS, MD

E1–02, P.O. Box 12233, Research

Triangle Park, NC 27709; telephone

(919) 541–3419.

Dated March 27, 1996.

Kenneth Olden,

Director, National Toxicology Program.

[FR Doc. 96–10835 Filed 4–30–96; 8:45 am]

BILLING CODE 4140–01–M

National Toxicology Program;

Availability of Technical Report on

Toxicology and Carcinogenesis

Studies of Methylphenidate

Hydrochloride

The HHS’ National Toxicology

Program announces the availability of

the NTP Technical Report on the

toxicology and carcinogenesis studies of

methylphenidate hydrochloride.

Methylphenidate hydrochloride is a

drug used in the treatment of narcolepsy

and attention deficit hyperactivity

disorders.

Toxicology and carcinogenicity

studies were conducted by

administration of methylphenidate

hydrochloride in feed to groups of 70

F344/N rats of each sex at doses of 0,

100, 500, or 1,000 ppm and to groups of

70 B6C3F1 mice of each sex at doses of

0, 50, 250, or 500 ppm.

Under the conditions of these 2-year

feed studies, there was no evidence of

carcinogenic activity 1 of